AstraZeneca, Daiichi Sanyko Partner for Flu VaccineBy
MedImmune, the biologics arm of AstraZeneca, has entered an agreement granting Daiichi Sankyo Company, Ltd. an exclusive license to develop and commercialize FluMist Quadrivalent in Japan. FluMist Quadrivalent is a live attenuated influenza vaccine which is administered as a nasal spray and contains four protective strains. Phase III safety and efficacy studies were conducted for FluMist Quadrivalent in Japanese children over the 2014-2015 influenza season and a regulatory submission is being prepared in Japan.
Under the agreement, Daiichi Sankyo will pay AstraZeneca an upfront fee with subsequent development milestones and sales-related payments post launch. Daiichi Sankyo will take on the full responsibility for the future development and commercialization of FluMist Quadrivalent in Japan and will hold the marketing authorization; AstraZeneca will supply FluMist Quadrivalent to Daiichi Sankyo.